Related Experiment Video
Updated: Jul 8, 2026

Testing Sensory and Multisensory Function in Children with Autism Spectrum Disorder
Published on: April 22, 2015
Melatonin for insomnia in children with autism spectrum disorders
Ivy M Andersen1, JoAnna Kaczmarska, Susan G McGrew
1Sleep Disorders Division, Department of Neurology, Vanderbilt University School of Medicine, Nashville, TN 37232-2551, USA.
Insights
Melatonin effectively improved sleep in most children with autism spectrum disorder (ASD), with few side effects. This suggests melatonin is a safe option for managing insomnia in this population.
Area of Science:
- Pediatrics
- Neurology
- Sleep Medicine
Background:
- Insomnia is a prevalent issue in children with autism spectrum disorder (ASD).
- Melatonin is frequently used off-label to manage sleep disturbances in pediatric populations.
Purpose of the Study:
- To evaluate the clinical experience of using melatonin for insomnia in children diagnosed with ASD.
- To assess the safety and tolerability of melatonin in this specific pediatric group.
Main Methods:
- Retrospective review of electronic medical records for 107 children (ages 2-18) with ASD who received melatonin.
- Parental counseling on sleep hygiene was provided to all participants.
- Clinical response was categorized based on parental reports of sleep improvement and concerns.
Main Results:
- 60% of children showed improved sleep, while 25% had sleep concerns resolved.
- Only 13% continued to experience significant sleep problems, and 1% reported worsened sleep.
- Mild side effects (morning sleepiness, enuresis) were reported in 3% of children; no increased seizures were observed.
Conclusions:
- Melatonin appears to be a safe and well-tolerated treatment for insomnia in children with ASD.
- The findings support the potential efficacy of melatonin for this indication.
- Further controlled trials are warranted to definitively establish melatonin's effectiveness in treating insomnia in children with ASD.
Abstract:
We describe our experience in using melatonin to treat insomnia, a common sleep concern, in children with autism spectrum disorders. One hundred seven children (2-18 years of age) with a confirmed diagnosis of autism spectrum disorders who received melatonin were identified by reviewing the electronic medical records of a single pediatrician. All parents were counseled on sleep hygiene techniques. Clinical response to melatonin, based on parental report, was categorized as (1) sleep no longer a concern, (2) improved sleep but continued parental concerns, (3) sleep continues to be a major concern, and (4) worsened sleep. The melatonin dose varied from 0.75 to 6 mg. After initiation of melatonin, parents of 27 children (25%) no longer reported sleep concerns at follow-up visits. Parents of 64 children (60%) reported improved sleep, although continued to have concerns regarding sleep. Parents of 14 children (13%) continued to report sleep problems as a major concern, with only 1 child having worse sleep after starting melatonin (1%), and 1 child having undetermined response (1%). Only 3 children had mild side-effects after starting melatonin, which included morning sleepiness and increased enuresis. There was no reported increase in seizures after starting melatonin in children with pre-existing epilepsy and no new-onset seizures. The majority of children were taking psychotropic medications. Melatonin appears to be a safe and well-tolerated treatment for insomnia in children with autism spectrum disorders. Controlled trials to determine efficacy appear warranted.
More Related Videos
Related Concept Videos
Management of Insomnia
Autism Spectrum Disorder
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.
Insomnia
Multiple factors contribute...
Nightmares and Night Terrors
Nightmares often...
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Modeling in Therapy
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in situations...
